Sparse AUC to Infinity and the Uncertainty of lambda.z

Summary and recommendations

For sparse sampling, where each animal gives one or a few samples:

  • Use the delta-method standard error for the AUC to infinity (the default). When little of the AUC is extrapolated, Yuan’s standard error, which treats \(\lambda_z\) as known, and the delta method both cover close to the nominal 95% (Yuan 94 to 96%). When about a fifth of the AUC is extrapolated, Yuan’s intervals are too narrow (81 to 89% coverage), and the delta method is closer to nominal (90 to 94%). Set sparse_lambda_z_se = "none" for Yuan’s method.
  • Give the AUC a concentration at time 0. As for any PKNCA AUC, the sparse AUC is NA without one. Sacrificial designs rarely sample at the dose, so after an extravascular dose impute zero with impute = "start_conc0". After an IV bolus, request the IV parameters (aucivlast, aucivinf.obs): they back-extrapolate \(C_0\) from the mean profile and include its uncertainty.
  • Treat the AUMC, and the MRT and Vss that come from it, with caution. The AUMC to infinity was biased low in most scenarios, and its confidence intervals under-covered in every scenario, even with the delta method (79 to 92%), most when elimination was slow.
  • The half-life of the mean profile is not the typical animal’s half-life. It was too long when the terminal phase was well sampled (by up to 11%) and too short when the profile was cut short by BLQ samples or a two-compartment distribution (down to -10%). Sample long enough to see at least three terminal half-lives.
  • Cmax of the mean profile reads high with few animals per time. Taking the maximum of noisy means near a broad peak overestimated Cmax by up to 10%.
  • Geometric-mean profiles were evaluated and not adopted. They were no more biased and were as precise or modestly more precise, but they estimate a different quantity (the typical animal rather than the population mean curve), need a rule for BLQ samples that drives their BLQ results, and fall outside the variance methods for sparse AUCs, which are for arithmetic means; adopting them would change all sparse calculations for a modest gain.
  • The bootstrap (sparse_bootstrap()) gives intervals for any parameter, but they are too narrow with few animals at each time. With three or four animals per time, its 95% intervals for the AUC to infinity covered 82 to 90% of the time. Prefer the analytical standard errors for the AUCs, and use the bootstrap for parameters and comparisons that have none, such as Cmax and ratios between groups. With 20 or more animals per time, its standard error was accurate and its intervals matched the delta method’s.
  • With many animals, the bias of the sparse estimate dominates. BLQ samples and the extrapolation of the mean profile biased the AUC to infinity low (by about 7% with BLQ samples here), whatever the number of animals and whichever half-life was used, so with many animals every confidence interval missed the truth more often than its nominal level.
  • The Tobit half-life was evaluated with BLQ samples and not adopted for the sparse AUC. The Tobit fit of the mean profile (hl_method = "tobit", with the LLOQ carried through the mean profile) gave nearly the same AUC to infinity as the log-linear fit, and it has no delta-method standard error. A (mixed-effects) Tobit fit of the individual samples was slightly less biased and more precise, but its standard error added to Yuan’s covered less well than the delta method with slow elimination (87 to 92% against 91 to 94%), and neither Tobit fit removed the bias that BLQ samples cause.

Introduction

With sparse sampling, each animal contributes only one or a few samples to a concentration-time profile, so there is no individual AUC to summarize. Instead, the AUC is estimated from the mean concentration at each time, and its standard error comes from the variability between animals at each time. Bailer (1988) gave the estimator and its variance for the AUC from time 0 to the last sampling time with serial sacrifice (one sample per animal). Nedelman and Jia (1998) extended it to designs where animals give more than one sample, with a Satterthwaite approximation for the degrees of freedom, and Holder (2001) gave an unbiased estimator of the covariance between times. Yuan (1993) extended Bailer’s method to the AUC from 0 to infinity by adding the extrapolation \(\bar{y}_n/\lambda_z\), treating the terminal elimination rate \(\lambda_z\) as known.

In practice, \(\lambda_z\) is estimated from the same data, so its uncertainty adds to that of the AUC to infinity. This vignette describes how PKNCA calculates the sparse AUC and AUMC to infinity with their standard errors and degrees of freedom, gives a delta-method extension of Yuan’s method that includes the uncertainty in \(\lambda_z\), extends both to IV bolus dosing, and compares the methods in a simulation-estimation study. A second study compares arithmetic and geometric mean profiles.

The sparse AUC to the last measurement

At each sampling time \(t_i\) (\(i = 0, \ldots, n\)), \(r_i\) animals are sampled and \(\bar{y}_i\) is the arithmetic mean concentration. \(r_{ij}\) animals are sampled at both \(t_i\) and \(t_j\) (\(r_{ii} = r_i\)). The linear trapezoidal AUC of the mean profile is a weighted sum of the means,

\[\widehat{AUC}_{0-t_{last}} = \sum_{i=0}^{n} w_i \bar{y}_i, \quad w_0 = \frac{t_1 - t_0}{2}, \quad w_i = \frac{t_{i+1} - t_{i-1}}{2}, \quad w_n = \frac{t_n - t_{n-1}}{2},\]

where \(t_n = t_{last}\) is the last time with a positive mean. Since the estimate is linear in the means, its variance is

\[\text{Var}\left(\widehat{AUC}_{0-t_{last}}\right) = \sum_{i}\sum_{j} w_i w_j \frac{r_{ij}\,\sigma_{ij}}{r_i r_j},\]

with \(\sigma_{ij}\) the covariance of the concentrations at \(t_i\) and \(t_j\) within an animal. PKNCA estimates \(\sigma_{ii}\) with the sample variance and \(\sigma_{ij}\) (\(i \neq j\)) with the unbiased estimator of Holder (2001), setting it to 0 when fewer than two animals are sampled at both times. With serial sacrifice, \(r_{ij} = 0\) for \(i \neq j\) and this is Bailer’s (1988) variance, \(\sum_i w_i^2 s_i^2/r_i\).

Only times up to \(t_{last}\) have weight. When more than half of the samples at a time are below the limit of quantification (BLQ), PKNCA sets that time’s mean to zero; times after the last positive mean are not part of \(AUC_{0-t_{last}}\), and they contribute nothing to its variance either.

As for any AUC in PKNCA, the area starts at the start of the interval, so a concentration is needed there, measured or imputed; without one, the sparse AUC is NA. Animals are rarely sampled at the dose in sacrificial designs, so after an extravascular dose the usual choice is to impute a concentration of zero with impute = "start_conc0". An imputed zero is known rather than measured, so it has weight in the estimate (as \(\bar{y}_0 = 0\)) but no variance.

Extrapolation to infinity (Yuan 1993)

With first-order terminal elimination, the area after \(t_{last}\) is \(\bar{y}_{n}/\lambda_z\), so

\[\widehat{AUC}_{0-\infty} = \sum_{i=0}^{n} w_i \bar{y}_i + \frac{\bar{y}_n}{\lambda_z}.\]

This is still linear in the means if \(\lambda_z\) is known, with the last weight increased by \(1/\lambda_z\). Yuan’s (1993) variance (his equation 4) is Bailer’s with that weight, \(g_n = w_n + 1/\lambda_z\):

\[\text{Var}\left(\widehat{AUC}_{0-\infty}\right) = \sum_{i}\sum_{j} g_i g_j \frac{r_{ij}\,\sigma_{ij}}{r_i r_j}, \qquad g_i = w_i + \frac{\delta_{i,n}}{\lambda_z}.\]

Written this way, the method applies to any sampling design, not only serial sacrifice.

The AUMC is the AUC of the moment curve \(t\,C(t)\). Its estimate uses the moment means \(\bar{m}_i = t_i \bar{y}_i\), and the extrapolation \(t_{last} C_{last}/\lambda_z + C_{last}/\lambda_z^2\) is \(\bar{m}_n\left(1/\lambda_z + 1/(t_{last}\lambda_z^2)\right)\), so the AUMC weights are \(g_i = w_i + \delta_{i,n}\left(1/\lambda_z + 1/(t_{last}\lambda_z^2)\right)\) applied to the moment means, with the covariances of the moments \(t_i t_j \sigma_{ij}\).

IV bolus: the back-extrapolated C0

After an IV bolus, the concentration at time 0 is not zero, and it cannot be measured. As for dense data, PKNCA estimates it from the mean profile with the methods of pk.calc.c0(): log-linear back-extrapolation from the first two means when they decline,

\[\hat{C}_0 = \bar{y}_1 \left(\frac{\bar{y}_1}{\bar{y}_2}\right)^{t_1/(t_2 - t_1)},\]

and otherwise \(\bar{y}_1\). The AUC adds the trapezoid from time 0 to \(t_1\), \(t_1(\hat{C}_0 + \bar{y}_1)/2\). \(\hat{C}_0\) is a smooth function of the first two means, so its uncertainty enters the variance through its gradient, as in the next section: the weights of \(\bar{y}_1\) and \(\bar{y}_2\) gain \((t_1/2)\,\partial \hat{C}_0/\partial \bar{y}_j\), with

\[\frac{\partial \hat{C}_0}{\partial \bar{y}_1} = \frac{\hat{C}_0\, t_2}{(t_2 - t_1)\,\bar{y}_1}, \qquad \frac{\partial \hat{C}_0}{\partial \bar{y}_2} = -\frac{\hat{C}_0\, t_1}{(t_2 - t_1)\,\bar{y}_2}.\]

With the linear trapezoidal rule, the AUMC from time 0 to \(t_1\) is \(t_1^2\bar{y}_1/2\) whatever \(C_0\) is, so \(C_0\) does not affect the AUMC. These are the sparse aucivlast, aucivall, and aucivinf.obs (and their AUMC equivalents), each with its standard error and degrees of freedom.

The uncertainty of lambda.z (delta method)

\(\lambda_z\) is estimated from the mean profile: PKNCA fits a line to the log mean concentrations at the half-life points, chosen automatically by the adjusted \(r^2\) (see vignette("v06-half-life-calculation")). For a given set of half-life points \(H\), the estimate is minus the least-squares slope,

\[\hat{\lambda}_z = -\sum_{j \in H} c_j \log \bar{y}_j, \qquad c_j = \frac{t_j - \bar{t}_H}{\sum_{k \in H}\left(t_k - \bar{t}_H\right)^2},\]

a smooth function of the means. So \(\widehat{AUC}_{0-\infty}\) is a smooth function of the means, and the delta method gives its variance from the same covariance of the means with the gradient in place of the weights:

\[g_j = \frac{\partial \widehat{AUC}_{0-\infty}}{\partial \bar{y}_j} = w_j + \frac{\delta_{j,n}}{\lambda_z} + \frac{\bar{y}_n}{\lambda_z^2}\,\frac{c_j}{\bar{y}_j}\,\mathbb{1}_{j \in H}.\]

The last term is the uncertainty in \(\lambda_z\). Because the gradient is taken with respect to all of the means together, the variance includes the covariance of \(\hat{\lambda}_z\) with \(\bar{y}_n\) and with \(\widehat{AUC}_{0-t_{last}}\). Those covariances matter: a high mean at an early half-life point raises the AUC to \(t_{last}\) but steepens the slope, which lowers the extrapolated area, so the two partly cancel. Adding a separately estimated variance of \(\hat{\lambda}_z\) to Yuan’s variance would miss that.

For the AUMC, with the moment means, \(\hat{\lambda}_z = -\sum_{j \in H} c_j \left(\log \bar{m}_j - \log t_j\right)\) and

\[g_j = w_j + \delta_{j,n}\left(\frac{1}{\lambda_z} + \frac{1}{t_{last}\lambda_z^2}\right) + \bar{m}_n\left(\frac{1}{\lambda_z^2} + \frac{2}{t_{last}\lambda_z^3}\right)\frac{c_j}{\bar{m}_j}\,\mathbb{1}_{j \in H}.\]

The method conditions on the selected half-life points: the variability from choosing them is not included. It is a first-order approximation, which is most accurate when the coefficient of variation of the means at the half-life points is small.

Degrees of freedom

Confidence intervals use a \(t\) distribution. The variance estimate is a quadratic form in the individual measurements \(y\), \(\hat{V} = y^T M y\), where \(M\) centers the measurements at each time and weights the products of each animal’s measurements by \(g_i g_j r_{ij}/(r_i r_j h_{ij})\), with \(h_{ij}\) the divisor of the Holder covariance. With \(\Omega\) the covariance of the measurements, Nedelman and Jia’s (1998) equation 6 gives the Satterthwaite degrees of freedom,

\[\nu = \frac{2\,E^2}{V}, \qquad E = \text{tr}(M\Omega), \qquad V = 2\,\text{tr}(M\Omega M\Omega).\]

With serial sacrifice, this is equation 6a of Nedelman, Gibiansky, and Lau (1995). PKNCA uses the same expression with the weights \(g\) for the AUC and AUMC to infinity, with or without the delta-method terms.

An alternative: lambda.z from the individual samples

Instead of the log means, \(\lambda_z\) could be estimated from every individual sample in the terminal phase, with its standard error from that regression. Samples below the limit of quantification are censored, so the regression is a Tobit regression on the log concentrations; when animals give more than one sample, a random intercept for each animal accounts for their correlation. The variance of \(\hat{\lambda}_z\) is then added to Yuan’s variance.

Two properties of this approach differ from the delta method. A line through the individual log concentrations follows the geometric-mean profile, while the AUC and \(C_{last}\) come from the arithmetic means; the two have the same terminal slope only when the between-animal coefficient of variation is the same at every terminal time. And the regression does not give the covariance of \(\hat{\lambda}_z\) with the means, so it is added as though it were independent. The simulation below compares both.

Simulation-estimation study

Design

Both studies in this vignette share one design (data-raw/sparse_simulation_design.R in the PKNCA source). Concentrations come from one- and two-compartment models (pmxTools) after a dose of 100, given orally or as an IV bolus, with log-normal between-animal variability (30% on each structural parameter) and a multiplicative residual error (15%) with mean 1:

  • One compartment: \(V\) 10, \(k_e\) 0.15/hr (fast elimination, half-life 4.6 hr) or 0.07/hr (slow, 9.9 hr), and oral \(k_a\) 5/hr (Tmax 0.7 to 0.9 hr).
  • Two compartments: \(V_1\) 10, \(V_2\) 15, \(Q\) 6, and \(CL\) chosen for the same terminal half-lives after a distribution phase with a half-life of about 0.5 hr; oral \(k_a\) 2.5/hr (Tmax 0.6 to 0.7 hr).

The slow elimination leaves about a fifth of the AUC to extrapolate after 24 hours, and the fast elimination less than a tenth. Two limits of quantification gave no BLQ samples or about a third of the samples at 24 hours BLQ (70% of the typical concentration at 24 hours). No animal was sampled at the dose. The serial-sacrifice design sampled 4 animals at each of 9 times (0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 hours for oral dosing; for IV bolus dosing, the first time was 5 minutes and 6 hours was omitted); the batch design sampled three batches of 4 animals, each batch at a third of those times. With 32 scenarios (two models, two routes, two designs, two limits of quantification, and two elimination rates), the standard error study had 5,000 replicates per scenario.

The truth is the AUC (and AUMC) from 0 to infinity of the population mean concentration curve, which is what the arithmetic means estimate: the mean of the individual values over 100,000 virtual animals (Monte Carlo standard error at most 0.24%). For each replicate, the oral concentration at time 0 was imputed as zero and the IV bolus \(C_0\) was back-extrapolated, the half-life was fit to the mean profile as PKNCA does, and three standard errors were calculated:

  • Yuan: \(\lambda_z\) treated as known (sparse_lambda_z_se = "none");
  • Delta: the delta method for \(\lambda_z\) (sparse_lambda_z_se = "delta");
  • Individual: \(\lambda_z\) and its standard error from a Tobit regression of the individual samples from the first half-life time onward (with a random intercept for each animal in the batch design), with that \(\lambda_z\) in the extrapolation and its variance added to Yuan’s.

The simulation is in data-raw/sparse_aucinf_simulation.R in the PKNCA source, which was run with PKNCA 0.12.1.9002 and pmxTools 1.5 (R version 4.6.1 (2026-06-24), 2026-10-07); every replicate has its own seed, so the results can be reproduced.

Results: coverage of the AUC to infinity

Model Route Design BLQ Elimination Extrap. (%) Coverage Yuan Coverage delta Coverage indiv. CI width Yuan CI width delta CI width indiv.
1-cmt oral serial none fast 4.5 94.9 95.5 94.9 41 42 40
1-cmt IV bolus serial none fast 4.4 95.9 96.3 95.8 44 45 43
1-cmt oral batch none fast 4.5 95.0 95.4 94.8 60 61 59
1-cmt IV bolus batch none fast 4.3 95.9 96.2 95.8 59 60 58
1-cmt oral serial moderate fast 7.2 93.7 95.1 94.1 41 44 40
1-cmt IV bolus serial moderate fast 6.8 94.4 95.7 94.7 45 47 44
1-cmt oral batch moderate fast 7.3 94.9 95.6 94.9 61 64 59
1-cmt IV bolus batch moderate fast 7.0 94.8 95.7 94.7 59 62 58
1-cmt oral serial none slow 21.1 84.5 90.6 85.7 45 64 46
1-cmt IV bolus serial none slow 20.6 86.7 91.2 87.3 45 61 45
1-cmt oral batch none slow 20.8 88.5 91.9 88.8 57 72 56
1-cmt IV bolus batch none slow 20.3 89.1 92.0 89.6 57 70 56
1-cmt oral serial moderate slow 20.9 82.9 92.2 88.8 51 77 54
1-cmt IV bolus serial moderate slow 20.7 85.7 93.6 90.2 52 74 55
1-cmt oral batch moderate slow 20.9 87.7 93.6 91.4 63 83 65
1-cmt IV bolus batch moderate slow 20.9 87.8 93.4 91.0 63 82 65
2-cmt oral serial none fast 3.5 94.4 95.2 94.6 31 32 31
2-cmt IV bolus serial none fast 3.3 93.7 95.1 94.2 32 33 32
2-cmt oral batch none fast 3.6 95.4 95.9 95.4 43 44 42
2-cmt IV bolus batch none fast 3.2 94.9 95.5 95.0 43 44 42
2-cmt oral serial moderate fast 4.9 94.1 95.7 94.9 31 33 31
2-cmt IV bolus serial moderate fast 4.6 94.1 95.5 94.6 32 34 32
2-cmt oral batch moderate fast 5.0 94.7 95.7 95.2 43 45 43
2-cmt IV bolus batch moderate fast 4.5 94.7 95.5 94.8 42 44 42
2-cmt oral serial none slow 18.4 83.6 90.2 84.7 34 50 34
2-cmt IV bolus serial none slow 17.6 85.5 91.6 86.3 33 47 34
2-cmt oral batch none slow 18.4 87.3 92.4 88.1 40 54 40
2-cmt IV bolus batch none slow 17.6 88.1 92.5 88.3 39 52 39
2-cmt oral serial moderate slow 17.9 81.3 91.9 87.8 41 61 44
2-cmt IV bolus serial moderate slow 17.1 83.6 92.1 88.7 40 58 42
2-cmt oral batch moderate slow 17.6 84.3 92.9 89.6 46 64 49
2-cmt IV bolus batch moderate slow 17.1 86.1 93.3 90.3 46 63 48

Results: coverage of the AUMC to infinity

Model Route Design BLQ Elimination Extrap. (%) Coverage Yuan Coverage delta Coverage indiv. CI width Yuan CI width delta CI width indiv.
1-cmt oral serial none fast 4.5 85.3 87.5 83.9 74 88 71
1-cmt IV bolus serial none fast 4.4 85.3 87.3 84.1 75 86 72
1-cmt oral batch none fast 4.5 86.9 88.8 85.6 84 95 80
1-cmt IV bolus batch none fast 4.3 86.3 87.7 85.1 82 91 78
1-cmt oral serial moderate fast 7.2 84.0 89.0 84.7 80 101 76
1-cmt IV bolus serial moderate fast 6.8 85.1 89.5 84.8 80 99 77
1-cmt oral batch moderate fast 7.3 88.1 91.8 88.3 91 111 87
1-cmt IV bolus batch moderate fast 7.0 86.5 89.9 86.1 88 107 84
1-cmt oral serial none slow 21.1 66.5 82.8 67.8 83 159 83
1-cmt IV bolus serial none slow 20.6 68.2 81.8 68.6 83 151 82
1-cmt oral batch none slow 20.8 68.5 82.1 68.0 86 153 81
1-cmt IV bolus batch none slow 20.3 69.8 82.5 69.3 86 146 81
1-cmt oral serial moderate slow 20.9 66.0 84.6 75.2 99 185 109
1-cmt IV bolus serial moderate slow 20.7 67.8 86.2 76.6 100 177 107
1-cmt oral batch moderate slow 20.9 69.4 85.6 77.5 102 178 107
1-cmt IV bolus batch moderate slow 20.9 69.7 85.8 77.6 101 171 106
2-cmt oral serial none fast 3.5 85.0 87.4 83.5 68 81 65
2-cmt IV bolus serial none fast 3.3 84.3 86.7 82.8 70 82 67
2-cmt oral batch none fast 3.6 86.7 88.7 85.6 78 89 74
2-cmt IV bolus batch none fast 3.2 85.4 87.5 83.9 77 87 73
2-cmt oral serial moderate fast 4.9 82.8 87.5 83.8 72 91 70
2-cmt IV bolus serial moderate fast 4.6 82.6 86.9 83.2 74 92 72
2-cmt oral batch moderate fast 5.0 85.0 89.5 86.3 81 98 80
2-cmt IV bolus batch moderate fast 4.5 84.0 87.5 84.0 79 95 77
2-cmt oral serial none slow 18.4 62.5 80.0 61.9 70 134 69
2-cmt IV bolus serial none slow 17.6 62.2 79.9 60.9 70 129 68
2-cmt oral batch none slow 18.4 64.5 81.2 62.8 74 135 69
2-cmt IV bolus batch none slow 17.6 62.9 79.2 61.2 72 129 69
2-cmt oral serial moderate slow 17.9 62.1 82.4 71.8 86 158 97
2-cmt IV bolus serial moderate slow 17.1 60.5 80.3 69.1 84 148 94
2-cmt oral batch moderate slow 17.6 62.1 81.9 72.3 87 154 97
2-cmt IV bolus batch moderate slow 17.1 62.8 81.7 71.4 87 151 96

Coverage is the percentage of 95% confidence intervals that contain the truth, and the CI width is the median width relative to the truth (%). The Monte Carlo standard error of each coverage is at most 0.7 percentage points.

Results: the bootstrap

The bootstrap of Shen and Machado (2017) (sparse_bootstrap()) was run on the first 2,000 data sets of each scenario with 200 replicates each, its default. Each replicate resampled the animals within each sampling time (or batch), and its AUC and AUMC to infinity were calculated as for the original data. Two intervals were formed: the percentile interval of the replicates and the estimate plus or minus 1.96 bootstrap standard errors (the standard deviation of the replicates). The delta method (on all of the scenario’s data sets, which include these) is shown for comparison.

Model Route Design BLQ Elimination Coverage percentile Coverage boot. SE Coverage delta CI width percentile CI width delta
1-cmt oral serial none fast 87.8 90.5 95.5 31 42
1-cmt IV bolus serial none fast 86.7 89.2 96.3 33 45
1-cmt oral batch none fast 85.4 86.8 95.4 41 61
1-cmt IV bolus batch none fast 86.3 88.6 96.2 41 60
1-cmt oral serial moderate fast 87.5 92.2 95.1 36 44
1-cmt IV bolus serial moderate fast 88.3 92.8 95.7 37 47
1-cmt oral batch moderate fast 88.0 89.9 95.6 46 64
1-cmt IV bolus batch moderate fast 87.0 89.6 95.7 44 62
1-cmt oral serial none slow 82.0 84.1 90.6 45 64
1-cmt IV bolus serial none slow 83.1 85.3 91.2 43 61
1-cmt oral batch none slow 81.8 84.2 91.9 48 72
1-cmt IV bolus batch none slow 81.6 83.8 92.0 47 70
1-cmt oral serial moderate slow 89.4 90.3 92.2 64 77
1-cmt IV bolus serial moderate slow 89.6 90.4 93.6 62 74
1-cmt oral batch moderate slow 89.6 91.1 93.6 67 83
1-cmt IV bolus batch moderate slow 89.6 90.1 93.4 63 82
2-cmt oral serial none fast 86.5 88.8 95.2 25 32
2-cmt IV bolus serial none fast 83.7 86.6 95.1 25 33
2-cmt oral batch none fast 84.9 87.4 95.9 30 44
2-cmt IV bolus batch none fast 84.0 87.1 95.5 30 44
2-cmt oral serial moderate fast 89.0 91.6 95.7 27 33
2-cmt IV bolus serial moderate fast 85.2 88.1 95.5 27 34
2-cmt oral batch moderate fast 87.3 90.0 95.7 33 45
2-cmt IV bolus batch moderate fast 86.4 89.8 95.5 32 44
2-cmt oral serial none slow 81.8 82.9 90.2 33 50
2-cmt IV bolus serial none slow 83.2 83.9 91.6 32 47
2-cmt oral batch none slow 82.4 84.4 92.4 35 54
2-cmt IV bolus batch none slow 83.2 83.9 92.5 35 52
2-cmt oral serial moderate slow 86.4 86.2 91.9 42 61
2-cmt IV bolus serial moderate slow 87.1 86.6 92.1 40 58
2-cmt oral batch moderate slow 86.7 86.9 92.9 45 64
2-cmt IV bolus batch moderate slow 89.0 89.2 93.3 44 63
Model Route Design BLQ Elimination Coverage percentile Coverage boot. SE Coverage delta CI width percentile CI width delta
1-cmt oral serial none fast 79.8 81.0 87.5 58 88
1-cmt IV bolus serial none fast 77.6 77.4 87.3 58 86
1-cmt oral batch none fast 78.6 79.0 88.8 61 95
1-cmt IV bolus batch none fast 79.1 80.0 87.7 61 91
1-cmt oral serial moderate fast 88.1 88.8 89.0 87 101
1-cmt IV bolus serial moderate fast 87.0 86.9 89.5 82 99
1-cmt oral batch moderate fast 87.9 89.0 91.8 92 111
1-cmt IV bolus batch moderate fast 87.4 87.1 89.9 87 107
1-cmt oral serial none slow 75.8 74.0 82.8 116 159
1-cmt IV bolus serial none slow 76.2 74.7 81.8 107 151
1-cmt oral batch none slow 75.6 73.9 82.1 108 153
1-cmt IV bolus batch none slow 74.8 73.8 82.5 102 146
1-cmt oral serial moderate slow 89.0 88.5 84.6 185 185
1-cmt IV bolus serial moderate slow 89.4 88.2 86.2 172 177
1-cmt oral batch moderate slow 90.0 89.6 85.6 180 178
1-cmt IV bolus batch moderate slow 89.4 89.4 85.8 162 171
2-cmt oral serial none fast 80.0 80.2 87.4 54 81
2-cmt IV bolus serial none fast 77.7 77.6 86.7 55 82
2-cmt oral batch none fast 78.0 78.9 88.7 57 89
2-cmt IV bolus batch none fast 76.0 76.7 87.5 57 87
2-cmt oral serial moderate fast 84.5 85.2 87.5 72 91
2-cmt IV bolus serial moderate fast 84.2 83.6 86.9 70 92
2-cmt oral batch moderate fast 86.1 86.7 89.5 76 98
2-cmt IV bolus batch moderate fast 85.5 85.2 87.5 73 95
2-cmt oral serial none slow 74.3 70.5 80.0 89 134
2-cmt IV bolus serial none slow 73.2 69.0 79.9 85 129
2-cmt oral batch none slow 74.7 71.6 81.2 87 135
2-cmt IV bolus batch none slow 71.8 68.9 79.2 85 129
2-cmt oral serial moderate slow 80.6 77.6 82.4 112 158
2-cmt IV bolus serial moderate slow 80.2 74.4 80.3 105 148
2-cmt oral batch moderate slow 82.8 80.1 81.9 113 154
2-cmt IV bolus batch moderate slow 83.5 79.0 81.7 110 151

Results: the bootstrap with more animals at each time

Published uses of the bootstrap had either a few animals per time (three mice in Takemoto et al. 2006, which compared only the means and standard deviations with Bailer’s) or many (about 88 subjects per time and treatment in the bioequivalence study of Shen and Machado 2017). To see how the number of animals per time changes the comparison, the two-compartment, oral, serial-sacrifice design with slow elimination was simulated with 4, 6, 10, 20, 50, 100 animals per time, without and with BLQ samples (2,000 data sets each, 200 bootstrap replicates; data-raw/sparse_bootstrap_n_profile.R). The data seeds do not depend on the number of animals, so 4 animals per time reproduces the data sets above. The bias is that of the point estimate, which all of the methods share.

BLQ Animals per time Coverage percentile Coverage boot. SE Coverage Yuan Coverage delta CI width percentile CI width delta Bias (%)
none 4 81.8 82.9 83.9 89.9 33 49 -2.3
none 6 84.9 85.3 81.4 90.4 30 38 -2.4
none 10 87.6 87.8 77.7 89.8 25 29 -2.2
none 20 89.8 89.6 79.8 90.0 19 20 -1.9
none 50 89.8 88.9 74.2 89.1 12 13 -1.8
none 100 86.3 85.9 69.4 85.6 9 9 -1.7
moderate 4 86.5 86.2 80.6 90.9 42 60 -6.1
moderate 6 89.2 87.5 76.2 88.2 38 44 -6.7
moderate 10 90.1 86.6 69.8 83.9 31 33 -6.7
moderate 20 84.3 78.8 55.8 74.3 22 22 -6.8
moderate 50 55.9 50.3 30.0 49.4 14 14 -7.0
moderate 100 29.2 26.0 11.2 25.8 10 10 -6.9
BLQ Animals per time Coverage percentile Coverage boot. SE Coverage Yuan Coverage delta CI width percentile CI width delta Bias (%)
none 4 74.3 70.5 62.9 79.8 89 135 -18.6
none 6 75.8 71.9 56.8 77.6 83 100 -18.5
none 10 77.0 72.2 48.9 73.6 68 75 -17.3
none 20 74.1 66.8 39.0 66.6 51 51 -16.7
none 50 59.0 52.5 21.0 51.8 33 33 -16.1
none 100 37.1 32.6 8.7 30.6 23 23 -15.9
moderate 4 80.6 77.6 60.5 81.3 112 154 -29.1
moderate 6 81.7 75.8 48.0 72.8 97 108 -29.4
moderate 10 78.8 71.0 37.9 63.1 80 79 -29.8
moderate 20 65.5 55.2 20.9 47.0 57 54 -29.4
moderate 50 24.6 18.0 3.9 16.2 34 33 -30.0
moderate 100 3.8 2.4 0.1 2.1 24 23 -29.5

Results: the Tobit half-life with BLQ samples

PKNCA can also fit the half-life by Tobit regression (hl_method = "tobit"), which treats BLQ samples as censored below the LLOQ rather than dropping them. For sparse data, it fits the mean profile, with the median LLOQ of the samples at each time and a time whose mean is BLQ censored. With the BLQ scenarios above (the first 1,000 data sets of each) and the BLQ arm of the profile over the number of animals per time (2,000 data sets at each number), three estimates of \(\lambda_z\) were compared: the log-linear fit of the mean profile (“log-linear”, as above), the Tobit fit of the mean profile (“Tobit mean”), and the Tobit fit of the individual samples (“Tobit indiv.”, as the “individual” method above). Each gave the AUC and AUMC to infinity from the same sparse AUC to \(t_{last}\) and mean at \(t_{last}\), with these intervals: Yuan’s and the delta method for the log-linear fit; Yuan’s for the Tobit fit of the mean profile, which has no standard error for \(\lambda_z\); Yuan’s variance plus that of \(\lambda_z\) for the Tobit fit of the individual samples; and, for each, the bootstrap percentile interval (200 replicates, each refitting its own \(\lambda_z\); data-raw/sparse_tobit_simulation.R).

Coverage (%) of the 95% intervals for the AUC to infinity, with four animals per time (three per batch):

Model Route Design Elimination Log-lin. Yuan Log-lin. delta Log-lin. boot. Tobit mean Yuan Tobit mean boot. Tobit indiv. Yuan+var Tobit indiv. boot.
1-cmt oral serial fast 94.9 96.3 88.0 94.5 87.9 95.5 87.7
1-cmt IV bolus serial fast 94.9 96.4 88.2 95.0 88.1 95.0 87.7
1-cmt oral batch fast 95.2 95.5 88.5 94.9 86.9 95.2 87.1
1-cmt IV bolus batch fast 94.9 96.2 87.3 94.7 87.5 94.7 87.0
1-cmt oral serial slow 82.7 92.9 88.8 82.0 82.2 89.0 82.8
1-cmt IV bolus serial slow 86.3 93.5 89.7 85.8 84.4 91.2 85.0
1-cmt oral batch slow 87.5 94.3 89.9 87.2 80.6 92.2 83.9
1-cmt IV bolus batch slow 89.1 93.8 90.3 88.8 84.1 91.5 85.4
2-cmt oral serial fast 94.2 95.6 90.2 94.5 89.4 94.7 89.4
2-cmt IV bolus serial fast 93.5 94.9 85.4 93.7 85.0 94.4 85.7
2-cmt oral batch fast 95.1 96.4 88.4 95.3 87.1 96.0 87.6
2-cmt IV bolus batch fast 95.2 95.8 87.2 95.4 86.7 95.5 86.8
2-cmt oral serial slow 80.6 90.9 86.5 80.6 78.9 86.7 80.1
2-cmt IV bolus serial slow 84.2 92.0 86.6 82.6 80.2 89.5 82.1
2-cmt oral batch slow 85.0 93.4 86.2 84.8 80.0 89.5 81.2
2-cmt IV bolus batch slow 86.0 93.6 88.9 86.3 80.9 90.4 83.3

And for the AUMC to infinity:

Model Route Design Elimination Log-lin. Yuan Log-lin. delta Log-lin. boot. Tobit mean Yuan Tobit mean boot. Tobit indiv. Yuan+var Tobit indiv. boot.
1-cmt oral serial fast 86.6 91.5 88.5 86.6 82.1 87.4 82.1
1-cmt IV bolus serial fast 84.6 89.2 86.8 83.5 79.4 84.9 79.3
1-cmt oral batch fast 88.9 91.8 88.4 87.8 81.6 88.8 82.2
1-cmt IV bolus batch fast 88.2 91.9 89.2 86.9 81.4 88.0 82.0
1-cmt oral serial slow 66.8 85.0 89.2 64.1 77.7 76.5 78.2
1-cmt IV bolus serial slow 67.5 85.1 89.0 65.2 77.2 76.0 77.9
1-cmt oral batch slow 67.5 86.3 89.8 64.7 74.8 77.1 77.6
1-cmt IV bolus batch slow 71.2 86.8 89.8 68.7 77.1 78.7 79.2
2-cmt oral serial fast 82.4 87.2 84.7 83.1 76.6 83.7 76.6
2-cmt IV bolus serial fast 84.6 88.3 85.1 85.0 79.0 85.3 79.0
2-cmt oral batch fast 84.3 87.7 85.9 84.3 78.3 85.2 78.2
2-cmt IV bolus batch fast 84.7 88.6 85.4 83.9 77.6 85.0 76.6
2-cmt oral serial slow 60.5 81.3 80.6 59.2 71.8 69.7 71.8
2-cmt IV bolus serial slow 61.4 80.5 80.6 59.4 73.4 68.9 72.5
2-cmt oral batch slow 64.2 82.6 83.1 62.2 74.0 74.3 74.3
2-cmt IV bolus batch slow 62.7 81.7 82.8 61.0 73.2 71.9 72.5

Bias and median absolute error (MAE), relative to the truth (%), of the AUC and then the AUMC to infinity with each \(\lambda_z\) (the point estimate does not depend on the interval):

Model Route Design Elimination Bias log-lin. Bias Tobit mean Bias Tobit indiv. MAE log-lin. MAE Tobit mean MAE Tobit indiv.
1-cmt oral serial fast 2.7 2.1 1.9 7.0 6.8 6.7
1-cmt IV bolus serial fast 3.0 2.4 2.1 8.1 8.1 7.6
1-cmt oral batch fast 2.6 1.7 1.4 9.2 9.0 8.9
1-cmt IV bolus batch fast 2.8 2.0 1.7 9.0 9.0 9.0
1-cmt oral serial slow -6.0 -6.6 -5.8 12.5 12.8 11.6
1-cmt IV bolus serial slow -6.0 -6.3 -5.7 11.8 11.9 11.0
1-cmt oral batch slow -4.9 -6.1 -5.1 13.1 13.5 12.1
1-cmt IV bolus batch slow -4.0 -5.5 -4.7 12.6 13.1 11.5
2-cmt oral serial fast 1.9 1.9 1.7 5.5 5.4 5.2
2-cmt IV bolus serial fast 4.0 4.0 3.6 6.2 6.1 6.0
2-cmt oral batch fast 2.1 1.9 1.4 7.0 7.0 6.7
2-cmt IV bolus batch fast 3.2 3.4 2.9 7.1 7.2 6.9
2-cmt oral serial slow -6.1 -6.2 -5.5 10.3 10.7 9.6
2-cmt IV bolus serial slow -5.3 -5.3 -4.9 9.9 10.3 8.9
2-cmt oral batch slow -5.7 -5.7 -5.0 10.4 10.8 9.4
2-cmt IV bolus batch slow -4.9 -4.8 -4.4 9.8 10.4 9.1
Model Route Design Elimination Bias log-lin. Bias Tobit mean Bias Tobit indiv. MAE log-lin. MAE Tobit mean MAE Tobit indiv.
1-cmt oral serial fast -5.1 -6.7 -7.1 16.4 16.4 14.7
1-cmt IV bolus serial fast -6.6 -8.2 -8.8 16.4 17.1 15.9
1-cmt oral batch fast -5.4 -7.5 -7.7 16.8 17.1 16.1
1-cmt IV bolus batch fast -7.0 -9.2 -10.3 17.0 17.5 16.0
1-cmt oral serial slow -23.1 -25.3 -21.8 35.4 37.5 31.8
1-cmt IV bolus serial slow -25.6 -26.8 -24.0 34.4 35.3 31.1
1-cmt oral batch slow -22.2 -25.5 -22.3 34.0 36.2 30.0
1-cmt IV bolus batch slow -21.6 -23.8 -21.6 33.0 35.4 28.5
2-cmt oral serial fast -8.5 -9.6 -10.4 16.0 16.6 15.5
2-cmt IV bolus serial fast -9.0 -8.9 -10.5 15.8 16.1 15.2
2-cmt oral batch fast -8.6 -9.3 -10.0 17.1 18.1 16.3
2-cmt IV bolus batch fast -9.8 -9.8 -11.2 17.0 17.6 16.5
2-cmt oral serial slow -29.1 -29.4 -26.3 34.8 36.0 32.2
2-cmt IV bolus serial slow -30.0 -29.9 -27.7 35.8 37.9 32.3
2-cmt oral batch slow -27.5 -27.9 -25.5 33.7 35.7 30.7
2-cmt IV bolus batch slow -28.8 -28.4 -27.1 35.0 37.1 31.9

Over the number of animals per time (two compartments, oral, serial sacrifice, slow elimination, BLQ samples), the coverage (%) and the bias (%) of the AUC to infinity:

Animals per time Log-lin. Yuan Log-lin. delta Log-lin. boot. Tobit mean Yuan Tobit mean boot. Tobit indiv. Yuan+var Tobit indiv. boot. Bias log-lin. Bias Tobit mean Bias Tobit indiv.
4 80.6 90.9 86.5 80.6 78.9 86.7 80.1 -6.1 -6.2 -5.5
6 76.2 88.2 89.2 75.3 81.3 83.9 83.0 -6.7 -6.7 -5.8
10 69.8 83.9 90.1 68.4 82.2 79.7 84.5 -6.7 -6.8 -5.6
20 55.8 74.3 84.3 55.5 77.1 69.4 79.2 -6.8 -6.9 -5.6
50 30.0 49.4 55.9 30.6 54.6 48.2 63.0 -7.0 -7.0 -5.6
100 11.2 25.8 29.2 11.3 30.6 27.4 43.5 -6.9 -6.8 -5.5

And of the AUMC to infinity:

Animals per time Log-lin. Yuan Log-lin. delta Log-lin. boot. Tobit mean Yuan Tobit mean boot. Tobit indiv. Yuan+var Tobit indiv. boot. Bias log-lin. Bias Tobit mean Bias Tobit indiv.
4 60.5 81.3 80.6 59.2 71.8 69.7 71.8 -29.1 -29.4 -26.3
6 48.0 72.8 81.7 47.5 72.0 60.2 72.5 -29.4 -30.1 -26.3
10 37.9 63.1 78.8 37.2 70.2 50.7 71.0 -29.8 -29.8 -26.0
20 20.9 47.0 65.5 22.0 58.1 36.0 60.8 -29.4 -29.7 -25.1
50 3.9 16.2 24.6 4.0 25.6 12.3 30.9 -30.0 -29.8 -25.4
100 0.1 2.1 3.8 0.1 4.2 1.8 8.3 -29.5 -29.5 -24.8

Results: accuracy of the point estimates

The point estimate with \(\lambda_z\) from the log means (“mean”, shared by Yuan and delta) and with \(\lambda_z\) from the Tobit fit of the individual samples (“indiv.”): bias, median absolute error (MAE), and root mean squared error (RMSE), all relative to the truth (%).

Model Route Design BLQ Elimination Bias mean Bias indiv. MAE mean MAE indiv. RMSE mean RMSE indiv.
1-cmt oral serial none fast 3.2 2.5 6.9 6.7 11.1 10.6
1-cmt IV bolus serial none fast 4.1 3.4 7.3 7.1 11.8 11.2
1-cmt oral batch none fast 3.4 2.6 9.2 9.1 14.7 14.0
1-cmt IV bolus batch none fast 3.7 3.0 8.7 8.6 14.3 13.7
1-cmt oral serial moderate fast 3.0 1.6 7.3 6.9 13.1 10.8
1-cmt IV bolus serial moderate fast 3.6 2.6 7.7 7.4 12.3 11.2
1-cmt oral batch moderate fast 3.5 2.1 9.3 8.9 16.7 14.5
1-cmt IV bolus batch moderate fast 3.8 2.6 9.3 9.1 15.5 14.2
1-cmt oral serial none slow 1.7 -0.2 9.9 9.7 19.9 17.5
1-cmt IV bolus serial none slow 1.4 -0.2 9.6 9.6 18.2 16.7
1-cmt oral batch none slow 1.6 -1.0 10.8 10.6 26.9 17.6
1-cmt IV bolus batch none slow 1.3 -0.8 10.7 10.5 21.7 18.3
1-cmt oral serial moderate slow 0.8 -2.4 12.4 11.4 103.9 20.8
1-cmt IV bolus serial moderate slow -0.4 -2.1 11.7 10.8 54.4 17.4
1-cmt oral batch moderate slow 0.3 -2.3 12.7 11.5 50.0 26.1
1-cmt IV bolus batch moderate slow 0.7 -1.6 12.7 11.7 60.8 48.7
2-cmt oral serial none fast 3.8 3.3 5.5 5.4 8.9 8.5
2-cmt IV bolus serial none fast 5.2 4.7 6.2 6.0 9.8 9.3
2-cmt oral batch none fast 3.9 3.4 6.8 6.5 10.6 10.2
2-cmt IV bolus batch none fast 5.1 4.6 7.1 6.8 11.4 10.9
2-cmt oral serial moderate fast 3.3 2.6 5.7 5.5 12.1 8.5
2-cmt IV bolus serial moderate fast 4.5 4.0 6.1 5.8 9.5 8.9
2-cmt oral batch moderate fast 3.3 2.5 6.8 6.6 12.1 10.2
2-cmt IV bolus batch moderate fast 4.3 3.7 6.9 6.7 11.4 10.7
2-cmt oral serial none slow -0.3 -1.5 7.8 7.9 12.7 12.2
2-cmt IV bolus serial none slow 0.2 -1.0 7.5 7.5 13.2 12.5
2-cmt oral batch none slow -0.2 -1.6 8.1 8.2 13.7 13.0
2-cmt IV bolus batch none slow 0.0 -1.2 7.9 7.9 13.5 12.6
2-cmt oral serial moderate slow -3.3 -2.9 10.2 9.5 15.6 14.0
2-cmt IV bolus serial moderate slow -3.1 -2.9 9.8 9.0 14.7 13.5
2-cmt oral batch moderate slow -3.4 -3.5 10.3 9.4 24.3 14.8
2-cmt IV bolus batch moderate slow -2.8 -2.7 9.8 9.0 15.4 14.1
Model Route Design BLQ Elimination Bias mean Bias indiv. MAE mean MAE indiv. RMSE mean RMSE indiv.
1-cmt oral serial none fast -0.7 -4.4 15.3 14.9 27.3 23.1
1-cmt IV bolus serial none fast -0.9 -4.7 15.9 15.5 33.3 24.8
1-cmt oral batch none fast -0.1 -4.2 16.5 16.0 43.5 29.4
1-cmt IV bolus batch none fast -2.2 -5.8 16.5 16.4 30.3 25.6
1-cmt oral serial moderate fast 1.6 -4.8 17.1 15.9 55.0 24.5
1-cmt IV bolus serial moderate fast -1.2 -5.7 16.6 16.0 33.8 24.6
1-cmt oral batch moderate fast 3.1 -3.7 16.9 16.0 98.4 47.0
1-cmt IV bolus batch moderate fast -0.1 -5.8 17.3 16.6 41.1 25.5
1-cmt oral serial none slow 3.0 -4.8 28.6 28.8 83.1 64.0
1-cmt IV bolus serial none slow 0.3 -6.1 27.7 27.8 77.7 70.4
1-cmt oral batch none slow 8.0 -8.7 27.9 27.1 556.4 53.9
1-cmt IV bolus batch none slow 1.5 -8.0 26.7 26.4 165.0 86.5
1-cmt oral serial moderate slow 172.3 -5.5 35.2 32.1 11262.8 156.6
1-cmt IV bolus serial moderate slow 38.3 -8.6 34.5 31.7 2893.8 63.7
1-cmt oral batch moderate slow 37.2 -0.5 33.7 29.4 1580.1 701.5
1-cmt IV bolus batch moderate slow 55.4 29.5 33.0 29.3 2504.9 2824.0
2-cmt oral serial none fast -1.5 -4.9 14.1 14.1 26.2 21.8
2-cmt IV bolus serial none fast -2.3 -5.7 15.5 15.4 28.2 25.4
2-cmt oral batch none fast -1.2 -4.6 15.3 14.9 27.0 23.3
2-cmt IV bolus batch none fast -2.7 -6.3 16.2 15.9 31.4 24.8
2-cmt oral serial moderate fast 0.2 -6.0 15.5 15.0 165.7 23.0
2-cmt IV bolus serial moderate fast -4.1 -7.3 16.2 15.9 28.9 23.3
2-cmt oral batch moderate fast -0.2 -5.9 16.6 15.7 72.2 23.7
2-cmt IV bolus batch moderate fast -3.8 -7.6 17.5 17.1 33.9 25.5
2-cmt oral serial none slow -9.2 -13.7 27.0 28.0 43.4 40.5
2-cmt IV bolus serial none slow -9.9 -14.5 27.6 28.9 50.2 48.4
2-cmt oral batch none slow -8.8 -13.8 26.6 27.9 47.0 42.9
2-cmt IV bolus batch none slow -10.2 -15.2 27.2 28.4 51.3 44.6
2-cmt oral serial moderate slow -15.6 -14.9 33.8 31.3 58.0 48.2
2-cmt IV bolus serial moderate slow -18.1 -17.4 35.4 32.8 53.2 50.7
2-cmt oral batch moderate slow -10.0 -16.4 33.9 31.0 471.3 74.6
2-cmt IV bolus batch moderate slow -17.3 -17.1 34.0 31.1 54.0 52.6

Findings

Coverage of the AUC to infinity. With fast elimination, when 3 to 7% of the AUC was extrapolated, all three methods covered close to the nominal 95% (Yuan 93.7 to 95.9%, delta 95.1 to 96.3%, individual 94.1 to 95.8%), so the uncertainty of \(\lambda_z\) matters little when little is extrapolated. With slow elimination, when 17 to 21% was extrapolated, treating \(\lambda_z\) as known under-covered (Yuan 81.3 to 89.1%), and the delta method was closest to nominal in every scenario (90.2 to 93.6%), though still a few points short. Adding the variance of \(\lambda_z\) from the individual samples (84.7 to 91.4%) recovered only part of the shortfall, because it omits the covariance of \(\hat{\lambda}_z\) with the means. The results were alike for the oral and IV bolus routes, so back-extrapolating \(C_0\) added little uncertainty, and alike for the one- and two-compartment models and the two designs.

Accuracy of the AUC to infinity. The bias of the AUC to infinity was -3.4 to 5.2%: slightly high with fast elimination, where the linear trapezoidal rule overestimates the area under the declining curve, and near zero with slow elimination (slightly low with two compartments and BLQ samples). The median absolute errors were similar for the two estimates of \(\lambda_z\), but the log-mean \(\lambda_z\) occasionally came out near zero with slow elimination and BLQ samples, which made the AUC to infinity heavy-tailed (RMSE up to 104%). The Tobit fit uses every terminal sample, including the censored ones, rather than means that count BLQ samples as zero, and it was steadier (RMSE up to 49%).

The AUMC to infinity. All three methods under-covered the AUMC in every scenario (delta 79 to 92%, Yuan 61 to 88%, individual 61 to 88%), most with slow elimination. Its extrapolation is proportional to \(1/\lambda_z^2\), so the first-order delta method is a poorer approximation, and the estimate is more heavy-tailed: its median absolute error was 14 to 35%, and with two compartments and slow elimination it was biased low (-18 to -9%), because the arithmetic mean of animals with different elimination rates declines ever more slowly, which a single exponential from \(t_{last}\) misses.

Interval width. The delta-method intervals were wider than Yuan’s, most when elimination was slow; the extra width is what improved the coverage.

The bootstrap. With three or four animals at each time, the bootstrap intervals were too narrow. For the AUC to infinity, the percentile interval covered 83.7 to 89.0% with fast elimination and 81.6 to 89.6% with slow elimination, against 95.1 to 96.3% and 90.2 to 93.6% for the delta method, and the interval from the bootstrap standard error was little better (82.9 to 92.8%). Resampling \(n\) animals understates the variance of their mean by the factor \((n - 1)/n\) (3/4 with four animals), and the percentile interval of a skewed estimate is narrow as well. For the AUMC to infinity, the bootstrap covered 71.8 to 90.0%: better than Yuan’s method when elimination was slow, and as good as or better than the delta method only with slow elimination and BLQ samples, where the first-order delta method is weakest. The bootstrap’s advantage is that it applies to every parameter and to ratios between groups (Shen and Machado 2017), including parameters with no analytical standard error, such as Cmax and the half-life; with few animals at each time, its intervals should be read as too narrow.

More animals at each time. The bootstrap improved with more animals, as its \((n - 1)/n\) shortfall shrank. Without BLQ samples, its percentile interval for the AUC to infinity covered 81.8% with 4 animals per time and 89.8% with 20, when the delta method covered 90.0%; with BLQ samples, it matched or passed the delta method from 6 animals per time. Its standard error was then as accurate as the delta method’s. But with many animals, every interval under-covered: with 100 animals per time, the percentile interval covered 86.3% without and 29.2% with BLQ samples (the delta method, 85.6% and 25.8%). The cause is the estimate, not its standard error: the sparse AUC to infinity was biased by -1.7% without and -6.9% with BLQ samples, whatever the number of animals, from the BLQ samples counted as zero in the late means and the extrapolation of a mean of animals with different elimination rates. More animals make every interval narrower around the same biased estimate, so no choice of interval corrects it. The AUMC to infinity, biased by -15.9% and -29.5%, showed the same pattern sooner.

The Tobit half-life. With BLQ samples, the Tobit fit of the mean profile changed little: the bias of the AUC to infinity was -6.6 to 4.0%, against -6.1 to 4.0% for the log-linear fit, and Yuan’s intervals covered the same. Its bootstrap intervals were narrower than the log-linear fit’s and covered less (79 to 84% against 86 to 90% with slow elimination), and with no standard error for \(\lambda_z\) it cannot use the delta method. The Tobit fit of the individual samples was slightly less biased and more precise: with 100 animals per time, its AUC to infinity was biased by -5.5% and its AUMC by -24.8%, against -6.9% and -29.5% for the log-linear fit. Its intervals were still less reliable than the delta method with few animals per time, and with many animals the bias left every interval short of nominal, whichever \(\lambda_z\) was used. So most of the bias that BLQ samples add does not come from \(\lambda_z\), and a better fit of \(\lambda_z\) does not remove it: it comes from the late means, where BLQ samples count as zero, and from the mean profile ending earlier, when more than half of a time’s samples are BLQ.

Arithmetic or geometric mean profiles

The sparse AUC uses the arithmetic mean at each time, whose profile is the population mean concentration curve. A geometric mean profile instead approximates the typical animal, and it may be less affected by animals with high concentrations. The second study compared the two for the AUClast, AUCinf, Cmax (\(C_0\) for IV bolus), AUMClast, AUMCinf, and half-life, using the same design with 2,000 replicates per scenario (data-raw/sparse_mean_type_simulation.R).

For each replicate, both mean profiles were formed, and pk.nca() calculated the parameters from each with the linear trapezoidal rule (imputing zero at time 0 for oral dosing and back-extrapolating \(C_0\) for IV bolus). For the geometric mean, a time with more than half of its samples BLQ was BLQ (as for the arithmetic sparse mean), and otherwise BLQ samples counted as half of the LLOQ. Each profile was compared with its own target (the arithmetic or geometric mean of the individual parameters of 50,000 virtual animals) and with the typical animal. Precision is the robust coefficient of variation (the interquartile range divided by 1.349, relative to the median).

Bias (median, %) and robust CV (%) over the scenarios; the last column counts the scenarios where the geometric robust CV was more than 1 point lower.
Parameter Bias vs own target, arith. Bias vs own target, geom. Bias vs typical, arith. Bias vs typical, geom. Robust CV, arith. Robust CV, geom. Geom. CV lower (scenarios)
AUClast -1 to 5 0 to 4 0 to 11 -3 to 3 6 to 15 6 to 15 1 of 32
AUCinf -6 to 5 -6 to 4 -2 to 13 -6 to 3 7 to 19 7 to 16 10 of 32
Cmax (C0 for IV) -4 to 10 -3 to 10 -1 to 15 -4 to 10 11 to 26 11 to 25 1 of 32
AUMClast -7 to 0 -5 to 1 -7 to 12 -11 to -3 10 to 23 11 to 22 5 of 32
AUMCinf -30 to -6 -19 to 1 -12 to 18 -18 to 1 19 to 50 18 to 39 28 of 32
Half-life -18 to 5 -14 to 3 -10 to 11 -12 to 3 20 to 34 16 to 29 17 of 32
Bias (%) of the half-life of the mean profile against the typical animal’s half-life, over routes and designs.
Model Elimination BLQ Arithmetic Geometric
1-cmt fast moderate 8 to 10 2 to 3
1-cmt fast none 9 to 10 -4 to -3
1-cmt slow moderate -6 to -2 -8 to -5
1-cmt slow none 2 to 3 -4 to -4
2-cmt fast moderate 6 to 8 0 to 1
2-cmt fast none 8 to 11 -5 to -2
2-cmt slow moderate -10 to -7 -12 to -9
2-cmt slow none -3 to 2 -9 to -5

Findings. Against their own targets, the two profiles were similarly accurate for the AUCs and Cmax. The geometric profile was as precise or more precise, most clearly for the half-life with BLQ samples and for the AUMC to infinity, but the gains were modest elsewhere. Both underestimated the AUMC to infinity (arithmetic -30 to -6%, geometric -19 to 1%). The half-life of the arithmetic mean profile was not consistently too short: it was too long when the terminal phase was well sampled, because the late mean is dominated by the slowly eliminating animals, and too short with BLQ samples (counted as zero in the late means) and in the two-compartment model with slow elimination, where the fitted points reach back toward the distribution phase. The geometric profile was generally a few percent short, because the geometric mean of exponentials declines at the average elimination rate.

The geometric profile was not adopted. Its gains were modest; it estimates a different quantity (the typical animal rather than the population mean curve); its BLQ rule (here, half the LLOQ) is a choice that drives its results with BLQ samples; and the sparse variance methods (Bailer, Nedelman and Jia, Holder) are for arithmetic means, so adopting it would change every sparse calculation.

Calculating it with PKNCA

Request aucinf.obs (or aumcinf.obs) with sparse data. The standard error and degrees of freedom are reported with it as aucinf.obs_se and aucinf.obs_df, and the summary shows the estimate with its standard error. These animals were not sampled at the dose, so the concentration at time 0 is imputed as zero.

d_sparse <-
  data.frame(
    time = rep(c(0.5, 1, 2, 4, 6, 8, 12, 24), each = 4),
    conc =
      c(3.1, 4.4, 3.6, 5.2,  5.8, 6.9, 5.1, 7.4,  7.2, 6.1, 8.3, 6.6,
        5.0, 6.2, 4.4, 5.6,  4.1, 3.4, 4.8, 3.7,  2.9, 3.5, 2.4, 3.1,
        1.6, 1.9, 1.3, 1.8,  0.33, 0.27, 0.41, 0.30)
  )
d_sparse$animal <- seq_len(nrow(d_sparse))
o_data <-
  PKNCAdata(
    PKNCAconc(d_sparse, conc ~ time | animal, sparse = TRUE),
    intervals = data.frame(start = 0, end = Inf, aucinf.obs = TRUE, aumcinf.obs = TRUE),
    impute = "start_conc0"
  )
o_nca <- pk.nca(o_data)
#> The sparse estimators use the linear trapezoidal rule, so the auc.method option
#> ("lin up/log down") does not apply to: aucinf.obs, aumcinf.obs
d_result <- as.data.frame(o_nca)
d_result[grepl("^au.*inf|^lambda.z$", d_result$PPTESTCD), c("PPTESTCD", "PPORRES")]
#> # A tibble: 7 × 2
#>   PPTESTCD       PPORRES
#>   <chr>            <dbl>
#> 1 lambda.z         0.139
#> 2 aucinf.obs      62.4  
#> 3 aucinf.obs_se    1.85 
#> 4 aucinf.obs_df   15.6  
#> 5 aumcinf.obs    468.   
#> 6 aumcinf.obs_se  20.2  
#> 7 aumcinf.obs_df   7.14
summary(o_nca)
#>  start end  aucinf.obs aumcinf.obs
#>      0 Inf 62.4 [1.85]  468 [20.2]
#> 
#> Caption: aucinf.obs, aumcinf.obs: estimate and standard error

The sparse_lambda_z_se option (set globally with PKNCA.options() or for one analysis with the options argument of PKNCAdata()) is "delta" (the default) for the delta method or "none" for Yuan’s method. The method used is recorded in the PPANMETH column.

After an IV bolus, request the IV parameters; \(C_0\) is back-extrapolated from the mean profile, and no imputation is needed.

d_sparse_iv <-
  data.frame(
    time = rep(c(0.25, 0.5, 1, 2, 4, 8, 24), each = 4),
    conc =
      c(9.1, 10.4, 8.7, 9.9,  8.8, 9.5, 8.1, 9.2,  8.2, 7.6, 8.9, 7.9,
        6.4, 7.1, 6.0, 6.9,  4.6, 4.1, 5.0, 4.3,  2.1, 1.8, 2.3, 1.9,
        0.10, 0.08, 0.12, 0.09)
  )
d_sparse_iv$animal <- seq_len(nrow(d_sparse_iv))
o_data_iv <-
  PKNCAdata(
    PKNCAconc(d_sparse_iv, conc ~ time | animal, sparse = TRUE),
    PKNCAdose(data.frame(time = 0, dose = 100), dose ~ time, route = "intravascular"),
    intervals = data.frame(start = 0, end = Inf, c0 = TRUE, aucivinf.obs = TRUE)
  )
d_result_iv <- as.data.frame(suppressWarnings(pk.nca(o_data_iv)))
#> The sparse estimators use the linear trapezoidal rule, so the auc.method option
#> ("lin up/log down") does not apply to: aucinf.obs, aucivinf.obs
d_result_iv[grepl("^c0$|^aucivinf", d_result_iv$PPTESTCD), c("PPTESTCD", "PPORRES")]
#> # A tibble: 4 × 2
#>   PPTESTCD        PPORRES
#>   <chr>             <dbl>
#> 1 c0                10.2 
#> 2 aucivinf.obs      58.0 
#> 3 aucivinf.obs_se    1.35
#> 4 aucivinf.obs_df    5.97

The warnings suppressed here say that the AUCs from time 0 without \(C_0\) (aucinf.obs, which aucivinf.obs depends on) are not calculated.

Discussion

When \(\lambda_z\) is estimated from the same samples, its uncertainty adds to that of the AUC to infinity, and treating it as known, as Yuan’s (1993) standard error does, under-covers once the extrapolated area is a substantial part of the AUC. The delta method on the log means is a consistent extension of Yuan’s method: it keeps his estimate, applies to serial-sacrifice and batch designs alike through the covariance of the means, includes the covariance of \(\hat{\lambda}_z\) with \(C_{last}\) and the AUC to \(t_{last}\), and needs nothing beyond the quantities already used for the sparse AUC to \(t_{last}\). In the simulation it brought the coverage of the AUC to infinity much closer to nominal when the extrapolated area was large (90.2 to 93.6%, against 81.3 to 89.1% for Yuan), though still a few points short, and it cost little when the extrapolated area was small. For this reason, it is PKNCA’s default (sparse_lambda_z_se = "delta"). The same delta method carries the uncertainty of the back-extrapolated \(C_0\) after an IV bolus, and the IV bolus scenarios covered as well as the oral ones.

Estimating \(\lambda_z\) from the individual samples with a (mixed-effects) Tobit regression gave a more stable point estimate when samples were BLQ, but adding its variance to Yuan’s did not give adequate coverage, and its mixed-effects fit was itself occasionally unstable in the batch design with BLQ samples and slow elimination. A bootstrap over animals, which includes the covariance of that \(\lambda_z\) with the means, was too narrow with few animals per time, as every bootstrap was. The Tobit fit of the mean profile, which uses the LLOQs, gave nearly the same results as the log-linear fit. Neither Tobit fit removed the bias of the sparse estimate with BLQ samples, which comes mostly from counting BLQ samples as zero in the late means and from the mean profile ending earlier; estimating those means with the censoring taken into account would be the place to reduce it.

Limitations remain. The delta method conditions on the selected half-life points, so the uncertainty of the automatic point selection is not included; it is a first-order approximation, which is least accurate when \(\lambda_z\) is imprecise, as for the AUMC with slow elimination; and the arithmetic mean profile of animals with different elimination rates is not monoexponential, so the extrapolation \(C_{last}/\lambda_z\) is itself biased for the population mean curve, which is part of why the AUMC to infinity is underestimated. Where the extrapolated area is large, sampling longer remains the better remedy.

References

Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. Journal of Pharmacokinetics and Biopharmaceutics. 1988;16(3):303-309.

Holder DJ. Comments on Nedelman and Jia’s extension of Satterthwaite’s approximation applied to pharmacokinetics. Journal of Biopharmaceutical Statistics. 2001;11(1-2):75-79. doi:10.1081/BIP-100104199

Nedelman JR, Gibiansky E, Lau DTW. Applying Bailer’s method for AUC confidence intervals to sparse sampling. Pharmaceutical Research. 1995;12(1):124-128.

Nedelman JR, Jia X. An extension of Satterthwaite’s approximation applied to pharmacokinetics. Journal of Biopharmaceutical Statistics. 1998;8(2):317-328. doi:10.1080/10543409808835241

Shen M, Machado SG. Bioequivalence evaluation of sparse sampling pharmacokinetics data using bootstrap resampling method. Journal of Biopharmaceutical Statistics. 2017;27(2):257-264. doi:10.1080/10543406.2016.1265543

Takemoto S, Yamaoka K, Nishikawa M, Takakura Y. Histogram analysis of pharmacokinetic parameters by bootstrap resampling from one-point sampling data in animal experiments. Drug Metabolism and Pharmacokinetics. 2006;21(6):458-464. doi:10.2133/dmpk.21.458

Yuan J. Estimation of variance for AUC in animal studies. Journal of Pharmaceutical Sciences. 1993;82(7):761-763. doi:10.1002/jps.2600820718